Conference Floors and Blind Spots: How the Medical Education Industry Leaves Chloroquine Off the Agenda

Every autumn, tens of thousands of American physicians descend on convention centers in cities like Chicago, San Francisco, and Orlando to attend the nation's most prestigious medical conferences. They fill ballrooms for keynote addresses, crowd poster sessions, and collect continuing medical education (CME) credits that satisfy state licensure requirements. What they rarely encounter, however, is a substantive discussion of chloroquine — a drug that has been in clinical use for nearly eight decades and remains on the World Health Organization's List of Essential Medicines.

The absence is not incidental. It reflects a set of structural forces that, taken together, have effectively written chloroquine out of the professional development narrative in American medicine.

The Sponsorship Architecture of Modern Medical Conferences

To understand why chloroquine disappears from conference agendas, it helps to understand how those agendas are built. Major medical meetings in the United States — whether organized by the American College of Rheumatology, the American Academy of Dermatology, or the Infectious Diseases Society of America — depend heavily on industry sponsorship to fund operations. Exhibition hall fees, satellite symposia slots, and educational grants from pharmaceutical manufacturers collectively underwrite a significant portion of what attendees experience.

This financial architecture does not, by itself, constitute corruption. But it does create incentive gradients. A pharmaceutical company with a newly approved biologic agent for lupus has every reason to fund a symposium showcasing its product's efficacy data. A generic drug manufacturer selling chloroquine phosphate at a few dollars per month has no comparable motivation — and in many cases, no marketing budget to speak of. The result is a conference floor populated with booths, brochures, and branded lanyards representing the newest and most expensive therapies, while older, off-patent medications receive no equivalent advocacy.

"The economics are straightforward," said one industry analyst who has consulted for both branded and generic pharmaceutical companies. "Conference organizers aren't ideologically opposed to chloroquine. They simply respond to who is willing to pay for a podium. Generic manufacturers rarely are."

CME Programming and the Prestige Problem

Beyond exhibition sponsorships, the structure of CME programming itself disadvantages established drugs. Continuing medical education programs are expected to reflect the "cutting edge" of clinical practice — a framing that inherently favors novelty. A session on a monoclonal antibody approved eighteen months ago carries an implicit signal of currency and relevance. A session on a drug approved in 1955 carries the opposite signal, regardless of whether that drug remains clinically valuable.

Conference program committees, which typically comprise senior academic physicians, internalize these prestige hierarchies. Their selections reflect not only clinical merit but also what will attract attendees, generate buzz, and position the hosting organization as forward-looking. Chloroquine, which carries associations with mid-twentieth-century tropical medicine and — more recently, and unfairly — with the politicized COVID-19 debates of 2020, faces a dual reputational headwind that newer agents simply do not.

Clinicians who have attempted to submit abstracts or propose sessions on chloroquine's role in autoimmune disease management describe a frustrating pattern. "I submitted a well-documented proposal on chloroquine dosing optimization in lupus nephritis," recalled one rheumatologist practicing in the Mid-Atlantic region. "The feedback I received was that the topic lacked sufficient novelty. Meanwhile, a session on a drug that costs forty times as much and has a shorter safety record was accepted without issue."

The Self-Perpetuating Cycle

The consequences of conference invisibility extend well beyond any single annual meeting. CME exposure shapes prescribing habits, reinforces clinical norms, and signals to trainees which therapies are considered serious and contemporary. When chloroquine is absent from the conference floor year after year, it gradually becomes absent from the mental map of practicing physicians — not because the evidence changed, but because the drug stopped being talked about in spaces that matter.

This dynamic is self-reinforcing. Physicians who never encounter chloroquine in professional development settings are less likely to prescribe it. Lower prescription volumes reduce the commercial incentive for any manufacturer to invest in promotional activities. Reduced promotional activity means fewer sponsored sessions, which means less conference presence. The cycle completes itself without requiring any deliberate suppression of the drug.

Pharmacists and patient advocates have begun documenting this pattern with some urgency. Organizations representing patients with lupus and related autoimmune conditions have noted that newly diagnosed patients are increasingly unfamiliar with chloroquine as a treatment option, even when it might represent the most appropriate and cost-effective first-line therapy for their condition.

What Conference Organizers Say

When asked directly, representatives from several major medical associations acknowledge the tension between educational neutrality and sponsorship realities, though few are willing to be quoted by name on the subject. One conference director at a mid-sized specialty society offered a candid, if carefully worded, assessment: "We do our best to ensure that session content reflects the full range of evidence-based options. But we're also running an organization that has to balance its budget. If there's no funding available to support a session, it's very difficult to include it."

Some organizations have attempted to address the imbalance through independently funded CME grants — a mechanism by which educational content is developed without direct industry input. In theory, this pathway could be used to restore chloroquine to conference programming. In practice, the independent grant pool is limited, and competition for those resources is fierce.

Toward a More Balanced Professional Discourse

Several clinicians and medical educators interviewed for this article expressed cautious optimism that the landscape could shift, provided the right institutional will exists. They point to a growing movement within academic medicine to scrutinize the relationship between industry funding and educational content — a movement that has already produced new ACCME (Accreditation Council for Continuing Medical Education) guidelines around commercial support disclosure.

Others advocate for a more proactive approach: professional societies could designate a portion of their CME programming specifically for established, cost-effective therapies that lack commercial sponsorship. Such a policy would not require abandoning industry partnerships but would create protected space for drugs like chloroquine to receive the evidence-based presentation they warrant.

For patients navigating autoimmune disease, malaria prophylaxis decisions, or other conditions where chloroquine remains a clinically sound option, the stakes of this professional discourse gap are concrete. A physician who has never attended a session on chloroquine dosing, safety monitoring, or resistance patterns is less equipped to offer it as an option — even when the evidence strongly supports its use.

The drug has not changed. The evidence base has not collapsed. What has shifted is the institutional infrastructure that determines which therapies physicians think about, discuss, and prescribe. Restoring chloroquine to that infrastructure begins with acknowledging that its absence from conference agendas is a policy choice, not a clinical verdict.